119 related articles for article (PubMed ID: 8585758)
1. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
[TBL] [Abstract][Full Text] [Related]
2. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
[TBL] [Abstract][Full Text] [Related]
3. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
[TBL] [Abstract][Full Text] [Related]
4. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Gao WY; Shirasaka T; Johns DG; Broder S; Mitsuya H
J Clin Invest; 1993 May; 91(5):2326-33. PubMed ID: 8387546
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
Kiso Y
Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.
Kageyama S; Weinstein JN; Shirasaka T; Kempf DJ; Norbeck DW; Plattner JJ; Erickson J; Mitsuya H
Antimicrob Agents Chemother; 1992 May; 36(5):926-33. PubMed ID: 1510415
[TBL] [Abstract][Full Text] [Related]
7. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
[TBL] [Abstract][Full Text] [Related]
8. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.
Gao WY; Agbaria R; Driscoll JS; Mitsuya H
J Biol Chem; 1994 Apr; 269(17):12633-8. PubMed ID: 8175673
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Yusa K; Kavlick MF; Kosalaraksa P; Mitsuya H
Antiviral Res; 1997 Dec; 36(3):179-89. PubMed ID: 9477118
[TBL] [Abstract][Full Text] [Related]
11. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
Medina DJ; Hsiung GD; Mellors JW
Antimicrob Agents Chemother; 1992 May; 36(5):1127-30. PubMed ID: 1510405
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
[TBL] [Abstract][Full Text] [Related]
15. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
[TBL] [Abstract][Full Text] [Related]
16. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
Cox SW; Albert J; Wahlberg J; Uhlén M; Wahren B
AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1229-34. PubMed ID: 1520536
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.
Cox SW; Apéria K; Albert J; Wahren B
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1725-9. PubMed ID: 7888232
[TBL] [Abstract][Full Text] [Related]
19. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
[TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
Dornsife RE; St Clair MH; Huang AT; Panella TJ; Koszalka GW; Burns CL; Averett DR
Antimicrob Agents Chemother; 1991 Feb; 35(2):322-8. PubMed ID: 1708977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
